Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.